{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}],"units":"Participants"}],"description":"Tumor assessment was performed every 8 weeks until disease progression. Objective response rate was defined as the percentage of patients who achieved a CR or a PR according to IWC 2014 criteria and assessed by an IOERC.\n\nCR: Target nodes/nodal masses must regress to \\<1.5 cm in LDi, no extralymphatic sites of disease, nonmeasured lesion is absent, disappearance of spleen or liver enlargement, no new lesions, no BM involvement.\n\nPR: ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites, nonmeasured lesions is absent/normal, regressed, but no increase, spleen must have regressed by \\>50% in length beyond normal, no new lesions.\n\nDisease subtype (PTCL-NOS, AITL, ALCL, ALK, EATL) was assessed by Central Pathology Review (CPR).","groups":[{"description":"PTCL Not Otherwise Specified","id":"OG000","title":"PTCL-NOS"},{"description":"Angioimmunoblastic T-cell lymphoma","id":"OG001","title":"AITL"},{"description":"Anaplastic Large-cell Lymphoma, ALK-","id":"OG002","title":"ALCL, ALK-"},{"description":"Enteropathy-associated T-cell lymphoma","id":"OG003","title":"EATL"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"PPS \\[Per Protocol Set\\]","reportingStatus":"POSTED","timeFrame":"Up to approximately 47 months.","title":"Objective Response Rate by Disease Subtype","type":"SECONDARY","unitOfMeasure":"Participants"}